Plts

Question 1

6 aspects of platelet function testing

Answer 1

adhesion tests, 
aggregation tests, 
assessment of the granular content, 
assessment of the release reaction, 
investigation of the prostaglandin pathways  
tests of platelet coagulant activity.

Question 2

Tests based on platelet aggregation

Answer 2

Light transmission
Impedance transmission
Impedance pot aggregation
Lumiaggregometry

Question 3

Tests based on platelet adhesion under shear

Answer 3

PFA

Global thrombosis test

Question 4

Cons pfa

Answer 4

Rigid closed system
Platelet count – HCT-dependent
Not sensitive to platelet secretion defects.

Question 5

Cons impact cone analyzer

Answer 5

Expensive
Experienced staff
Lack of clinical studies
Not widely available

Question 6

Cons global thrombosis time

Answer 6

Lack of clinical studies

Not widely available

Question 7

Cons TEG

Answer 7

Limited HCT and platelet count range (for platelet system)

Lack of clinical studies

Question 8

PRo’s pfa

Answer 8

In vitro standardized BT
Easy, quick POCT
Sensitive to severe platelet defects

Question 9

Pro lta

Answer 9

Historical gold standard
Diagnostic method
Flexible
Different platelet pathways investigated
Sensitive to anti-plt therapy

Question 10

Pro of rotem plts

Answer 10

POCT
Predicts bleeding
Reduces blood transfusions
Improves clinical outcome
Global hemostasis test
WB platelet aggregometry

Question 11

What must be present for normal RIPA

Answer 11

Fxnal vwf

Gp 1b/9/5 receptor

Question 12

How to confirm do BSS

Answer 12

Flow showing absence GP1 absence of ristocetinnresponse

Question 13

What is defect in BSS

Answer 13

Absence of gp1b/IX/v receptor- which binds to vwf

Question 14

Glanzsmans

Answer 14

GPIIb/IIIa (ITG αIIbβ3), either qualitative or quantitative, which results in faulty platelet aggregation and diminished clot retraction.

Question 15

Light transmission aggregometry

Answer 15

Centrifuged platelet-rich plasma samples are monitored before and after the addition of an agonist (ADP, collagen, epinephrine, arachidonic acid, ristocetin, thrombin receptor activating peptide, and thromboxane A2 mimetic), assessing shape change, lag phase, percent of aggregation, slope of aggregation, and deaggregation

Question 16

Plt agg resukt for gt

Answer 16

Failure to aggregate with all agonists except ristocetin

Question 17

Dx glanzsmans

Answer 17

Can have normal cbe
Normal risto
Prolonged pfa
Reduced cd41 and cd 61 on flow with normal cd 42
Genomic DNA sequencing of the 45 exons comprising the αIIbβ3 unit, along with the splice sites of the ITGB3 and ITGA2B gene, should be investigated, and the established mutations should be confirmed with a second DNA sample analysis.